Oncolytics Biotech Inc. (NASDAQ:ONCY) Short Interest Down 14.1% in February

Oncolytics Biotech Inc. (NASDAQ:ONCY) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 3,050,000 shares, a drop of 14.1% from the January 31st total of 3,550,000 shares. Based on an average trading volume of 1,150,000 shares, the days-to-cover ratio is presently 2.7 days.

Oncolytics Biotech Stock Performance

Shares of NASDAQ ONCY traded down $0.01 during mid-day trading on Thursday, reaching $0.72. The company had a trading volume of 211,962 shares, compared to its average volume of 1,422,453. Oncolytics Biotech has a one year low of $0.60 and a one year high of $1.53. The business’s 50-day simple moving average is $0.80 and its 200 day simple moving average is $0.94. The firm has a market cap of $61.82 million, a price-to-earnings ratio of -2.68 and a beta of 1.18.

Institutional Trading of Oncolytics Biotech

A number of institutional investors and hedge funds have recently made changes to their positions in the company. International Assets Investment Management LLC boosted its position in Oncolytics Biotech by 15.0% in the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after buying an additional 26,069 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Oncolytics Biotech in the fourth quarter worth about $90,000. Geode Capital Management LLC lifted its position in Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock valued at $61,000 after purchasing an additional 24,997 shares during the last quarter. National Bank of Canada FI raised its stake in shares of Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after acquiring an additional 42,955 shares in the last quarter. Finally, Vantage Point Financial LLC bought a new position in shares of Oncolytics Biotech during the 4th quarter valued at $27,000. Institutional investors own 6.82% of the company’s stock.

Wall Street Analysts Forecast Growth

ONCY has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a research note on Monday, February 3rd. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th. Finally, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.